ClinicalTrials.gg
Not yet recruitingNCT07939828COL'CHICUpdated Nov 16, 2026

Sarcoma With EWSR1/FUS : POU2AF3 (COLCA2) Fusion : Molecular and Clinicopathologic Characterization of a Case Series.

An observational study in Sarcoma, sponsored by University Hospital, Strasbourg, France. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University Hospital, Strasbourg, France · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Study summary

Sarcomas with the EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript represent a new molecularly defined entity, first described in 2023 (1). There are 24 cases reported in the literature, including 3 descriptive series totaling 19 cases (1-3). Clinically, this is an aggressive entity affecting patients of varying ages (16-74 years), most commonly located in the sinonasal tract, and capable of involving both bone and soft tissue. A few extrasinonasal cases have also been reported. Histologically, two morphological groups have been described (3): the first group (the rarest) is characterized by a low-grade morphology with non-atypical spindle cells; the second group is morphologically high-grade, featuring spindle, round, or epithelioid cells and possible divergent differentiation (epithelial, neuroendocrine, striated muscle, or bone).

The immunophenotype of these lesions is nonspecific, with variable positivity for various markers such as S100, CD99, AE1/3, CD56, chromogranin, synaptophysin, SATB2, CD117, GFAP, and EMA.

Given the clinical, morphological, and immunohistochemical features of this entity, numerous differential diagnoses can be considered: synovial sarcoma, malignant tumor of the peripheral nerve sheaths, Ewing sarcoma, myoepithelial tumor, biphenotypic sinonasal sarcoma, etc.

02

Conditions studied

  • Sarcoma

Browse trials for

03

In context

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 365 are open to participants now.

This study's planned enrollment of 10 is below the median of 120 across 218 observational studies indexed under Sarcoma.

Browse Sarcoma studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

sarcomas

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient whose test results indicated "the presence of a fusion transcript involving the POU2AF3 gene (formerly COLCA2)"
  • Adult patient
  • Who has consented to the reuse of their samples for scientific and medical research related to their condition or related conditions

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • SARCOMA

    Sarcomas exhibiting an EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript

    Biological: methylation profiling

Interventions

  • Biologicalmethylation profiling

    methylation profiling

06

What researchers measure

Primary outcomes

  1. Clustering Common to methylation analysis and RNA-seq.

    Determine whether sarcomas with the EWSR1/FUS :: POU2AF3 fusion transcript constitute a distinct entity

    Time frame: 11 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939828
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

WEINGERTNER Noëlle, MD
Contact
noelle.weingertner@chru-strasbourg.fr
+33388128241

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion